Drug Trial Radar · NCT06081907
The Efficacy and Safety of IBI363 in Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
430
Planned (sponsor's estimate)
Start
Dec 25, 2023
Primary completion
Dec 1, 2026
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Hunan Province Tumor HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Xiangya Hospital of Central South University
- First posted
- Oct 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a prospective multi-cohort clinical study. The study is divided into two phases, Phase Ia and Phase Ib. In Phase Ia, a dose escalation portion was conducted using a 3+3 dose-escalation design, with a preference for enrolling subjects with advanced non-small cell lung cancer and melanoma. Phase Ib represents the cohort expansion phase, comprising seven cohorts.
Conditions
- Advanced Solid Tumor
Interventions
IBI363Drug
IBI363 is based on the "3+3" model with a dose of 1 mg/kg Q3W. IBI325, 20 mg/kg Q3W.
IBI363Drug
IBI363 is based on the "3+3" model with a dose of 1.5 mg/kg Q3W. IBI325, 20 mg/kg Q3W.
IBI363Drug
IBI363 is based on the "3+3" model with a dose of 600 μg/kg Q2W. Lenvatinib, 8mg QD.
IBI363Drug
IBI363 is based on the "3+3" model with a dose of 1000 μg/kg Q2W. Lenvatinib, 8mg QD.
IBI363Drug
The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventTime frame: Up to 90 days post last dose
- ORRTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yongchang Zhang
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.